Polo-like kinase 1: a potential therapeutic option in combination with conventional chemotherapy for the management of patients with triple-negative breast cancer.
暂无分享,去创建一个
Emmanuel Barillot | Anne Vincent-Salomon | Guillem Rigaill | David Gentien | Elisabetta Marangoni | Thierry Dubois | Sergio Roman-Roman | E. Barillot | A. Vincent-Salomon | S. Roman-Roman | T. Dubois | S. Depil | B. Tesson | E. Marangoni | D. Gentien | D. Decaudin | G. Rigaill | F. Némati | L. de Koning | Bruno Tesson | Virginie Maire | Francisco Cruzalegui | Gordon C Tucker | Didier Decaudin | V. Maire | M. Richardson | E. Gravier | Bérengère Marty-Prouvost | G. Lang | A. Dumont | A. Pierré | F. Cruzalegui | G. Tucker | Eléonore Gravier | Marion Richardson | Bérengère Marty-Prouvost | Leanne De Koning | Aurélie Dumont | Stéphane Depil | Alain Pierré | Fariba Némati | Guillaume Lang | A. Pierré
[1] A. Jimeno,et al. Phase I study of ON 01910.Na, a novel modulator of the Polo-like kinase 1 pathway, in adult patients with solid tumors. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] W. Weichert,et al. Polo-like kinase isoforms in breast cancer: expression patterns and prognostic implications , 2005, Virchows Archiv.
[3] D. Longo,et al. Malignant transformation of mammalian cells initiated by constitutive expression of the polo-like kinase. , 1997, Biochemical and biophysical research communications.
[4] R. Kaiser,et al. Phase I dose escalation and pharmacokinetic study of BI 2536, a novel Polo-like kinase 1 inhibitor, in patients with advanced solid tumors. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] Genee Y. Lee,et al. Three-dimensional culture models of normal and malignant breast epithelial cells , 2007, Nature Methods.
[6] M. Pegram,et al. Triple negative breast cancer: unmet medical needs , 2011, Breast Cancer Research and Treatment.
[7] M. Lei,et al. Normal Cells, but Not Cancer Cells, Survive Severe Plk1 Depletion , 2006, Molecular and Cellular Biology.
[8] M. Poupon,et al. CD44 targeting reduces tumour growth and prevents post-chemotherapy relapse of human breast cancers xenografts , 2009, British Journal of Cancer.
[9] Anne Vincent-Salomon,et al. Molecular profiling of patient-derived breast cancer xenografts , 2012, Breast Cancer Research.
[10] A. Ullrich,et al. Targeting polo-like kinase 1 for cancer therapy , 2006, Nature Reviews Cancer.
[11] Christian A. Rees,et al. Molecular portraits of human breast tumours , 2000, Nature.
[12] R. Grobholz,et al. Polo-like kinase: a novel marker of proliferation: correlation with estrogen-receptor expression in human breast cancer. , 2000, Pathology, research and practice.
[13] Birgit Gaschler-Markefski,et al. The Efficacy and Safety of BI 2536, a Novel Plk-1 Inhibitor, in Patients with Stage IIIB/IV Non-small Cell Lung Cancer Who Had Relapsed after, or Failed, Chemotherapy: Results from an Open-Label, Randomized Phase II Clinical Trial , 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[14] Péter Lénárt,et al. BI 2536, a Potent and Selective Inhibitor of Polo-like Kinase 1, Inhibits Tumor Growth In Vivo , 2007, Current Biology.
[15] S. Dunn,et al. Small interfering RNA library screen identified polo-like kinase-1 (PLK1) as a potential therapeutic target for breast cancer that uniquely eliminates tumor-initiating cells , 2012, Breast Cancer Research.
[16] K. Kinzler,et al. A panel of isogenic human cancer cells suggests a therapeutic approach for cancers with inactivated p53 , 2009, Proceedings of the National Academy of Sciences.
[17] Michael J. Emanuele,et al. A Genome-wide RNAi Screen Identifies Multiple Synthetic Lethal Interactions with the Ras Oncogene , 2009, Cell.
[18] T. Yap,et al. Phase I Study of GSK461364, a Specific and Competitive Polo-like Kinase 1 Inhibitor, in Patients with Advanced Solid Malignancies , 2011, Clinical Cancer Research.
[19] Mieke Schutte,et al. Phosphatidylinositol-3-OH Kinase or RAS Pathway Mutations in Human Breast Cancer Cell Lines , 2007, Molecular Cancer Research.
[20] C. Swanton,et al. Targeting polo-like kinase: learning too little too late? , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] Irmtraud M. Meyer,et al. The clonal and mutational evolution spectrum of primary triple-negative breast cancers , 2012, Nature.
[22] K. Shokat,et al. A chemical screen in diverse breast cancer cell lines reveals genetic enhancers and suppressors of sensitivity to PI3K isoform-selective inhibition. , 2008, The Biochemical journal.
[23] R. Medema,et al. Shared and separate functions of polo-like kinases and aurora kinases in cancer , 2010, Nature Reviews Cancer.
[24] M. Malumbres,et al. From Plk1 to Plk5 , 2011, Cell cycle.
[25] A. Vincent-Salomon,et al. A New Model of Patient Tumor-Derived Breast Cancer Xenografts for Preclinical Assays , 2007, Clinical Cancer Research.
[26] Ran Guan,et al. Small interfering RNA-mediated Polo-like kinase 1 depletion preferentially reduces the survival of p53-defective, oncogenic transformed cells and inhibits tumor growth in animals. , 2005, Cancer research.
[27] J. Wrana,et al. Small molecule kinase inhibitor screen identifies polo-like kinase 1 as a target for neuroblastoma tumor-initiating cells. , 2011, Cancer research.
[28] K. Strebhardt,et al. Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy , 2010, Nature Reviews Drug Discovery.
[29] R Core Team,et al. R: A language and environment for statistical computing. , 2014 .
[30] K. Hess,et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] Emmanuel Barillot,et al. Frequent PTEN genomic alterations and activated phosphatidylinositol 3-kinase pathway in basal-like breast cancer cells , 2008, Breast Cancer Research.
[32] Genee Y. Lee,et al. The morphologies of breast cancer cell lines in three‐dimensional assays correlate with their profiles of gene expression , 2007, Molecular oncology.
[33] Joel Greshock,et al. Sensitivity of Cancer Cells to Plk1 Inhibitor GSK461364A Is Associated with Loss of p53 Function and Chromosome Instability , 2010, Molecular Cancer Therapeutics.
[34] Jorge S Reis-Filho,et al. Triple-negative breast cancer. , 2010, The New England journal of medicine.
[35] F. Bertucci,et al. Sixteen-kinase gene expression identifies luminal breast cancers with poor prognosis. , 2008, Cancer research.
[36] Kyle A. Emmitte,et al. In vitro biological activity of a novel small-molecule inhibitor of polo-like kinase 1 , 2007, Molecular Cancer Therapeutics.
[37] M. Bissell,et al. Polo-like kinase 1 is involved in invasion through extracellular matrix. , 2007, Cancer research.
[38] Zhi Hu,et al. An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. , 2008, Cancer research.
[39] A. Ashworth,et al. Hallmarks of 'BRCAness' in sporadic cancers , 2004, Nature Reviews Cancer.
[40] Valérie Gailus-Durner,et al. Toxicity modelling of Plk1-targeted therapies in genetically engineered mice and cultured primary mammalian cells , 2011, Nature communications.
[41] R. Kaiser,et al. Phase i study of the Plk1 inhibitor BI 2536 administered intravenously on three consecutive days in advanced solid tumours. , 2012, Current oncology.
[42] Liang Cheng,et al. Polo-like Kinase 1 Facilitates Loss of Pten Tumor Suppressor-induced Prostate Cancer Formation , 2011, The Journal of Biological Chemistry.
[43] A. Thompson,et al. Immunohistochemical detection of Polo-like kinase-1 (PLK1) in primary breast cancer is associated with TP53 mutation and poor clinical outcome , 2012, Breast Cancer Research.
[44] A. Vincent-Salomon,et al. High frequency of TP53 mutation in BRCA1 and sporadic basal-like carcinomas but not in BRCA1 luminal breast tumors. , 2009, Cancer research.
[45] R. Hofheinz,et al. Clinical Cancer esearch cer Therapy : Clinical Open-Label , Phase I Study of the Polo-like Kinase-1 bitor , BI 2536 , in Patients with Advanced R d Tumors , 2010 .
[46] Paul Ellis,et al. Dissecting the heterogeneity of triple-negative breast cancer. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.